Furthermore, the P2Y purinergic receptor 1 (P2RY1), which has been shown to serve as an unfavorable prognostic marker in renal and non-melanoma skin cancers ([61], (Human Protein Atlas)), is also predicted to promote LUAD tumor progression at the stage 2–3 interface (Figure 5B). This evidence concerns the gene P2RY1 and non-melanoma skin carcinoma.